RecruitingInterventional · Phase 2/3NCT03435796 ↗Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Active, not recruitingInterventional · Phase 2NCT03505320 ↗A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 PositiveManish A ShahPIInterventionDrug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: Pembrolizumab · Drug: folinic acid · Drug: nivolumab · Drug: DocetaxelDatesJun 2018 – Jun 2027 (est.)SponsorAstellas Pharma Inc.Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more
Active, not recruitingInterventional · Phase 3NCT03653507 ↗A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaManish A ShahPIInterventionDrug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine · Drug: placeboDatesNov 2018 – Oct 2022· Results postedSponsorAstellas Pharma Global Development, Inc.Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
RecruitingInterventional · Phase 2NCT03899155 ↗Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesAna M. MolinaPIInterventionDrug: Nivolumab · Drug: Ipilimumab · Drug: Cabozantinib · Drug: Trametinib · Drug: Relatlimab · Drug: Nivolumab + Relatlimab · Drug: Capecitabine · Drug: Bevacizumab · Drug: Temozolomide · Drug: Rucaparib · Drug: Daratumumab · Drug: Regorafinib · Drug: Leucovorin · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Enzalutamide · Drug: Sunitinib · Drug: Pemetrexed · Drug: PembrolizumabDatesAug 2019 – Aug 2029 (est.)SponsorBristol-Myers Squibb CompanyCancer
Active, not recruitingInterventional · Phase 1/2NCT04041310 ↗A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsManish A ShahPIInterventionBiological: GAd-209-FSP low dose · Biological: MVA-209-FSP low dose · Biological: GAd-209-FSP high dose · Biological: MVA-209-FSP high dose · Biological: GAd20-209-FSP, RP2D · Biological: MVA-209-FSP, RP2D · Drug: KEYTRUDA®DatesOct 2019 – Oct 2026 (est.)SponsorNousCom SRLSolid Tumor, Adult
Active, not recruitingInterventional · Phase 1NCT04454658 ↗A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With MyelofibrosisEllen K. RitchiePIInterventionDrug: ABBV-744 · Drug: Navitoclax · Drug: RuxolitinibDatesNov 2020 – Jan 2027 (est.)SponsorAbbVie Inc.Myelofibrosis (MF)
Active, not recruitingInterventional · Phase 2NCT04486378 ↗A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following ResectionManish A ShahPIInterventionDrug: RO7198457 intravenous (IV) · Other: Observational group (no intervention)DatesMar 2021 – Nov 2026 (est.)SponsorBioNTech SEColorectal Cancer Stage IIColorectal Cancer Stage III
RecruitingInterventional · Not applicableNCT04515810 ↗Planning Advance Care Together (PACT) to Improve Engagement in Advance Care PlanningMegan Johnson ShenPIInterventionOther: Internet-Based Intervention · Other: Best Practice · Other: Telephone-Based Intervention · Other: Questionnaire Administration · Other: Post-intervention qualitative feedback interviewDatesFeb 2025 – May 2027 (est.)SponsorWeill Medical College of Cornell UniversityLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Hematologic Malignancy+1 more
Active, not recruitingInterventional · Phase 3NCT04964934 ↗A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch StudyMassimo CristofanilliPIInterventionDrug: AZD9833 · Drug: AZD9833 Placebo · Drug: Anastrozole · Drug: Anastrozole placebo · Drug: Letrozole · Drug: Letrozole placebo · Drug: Palbociclib · Drug: Abemaciclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist · Drug: RibociclibDatesJun 2021 – Jun 2025SponsorAstraZeneca, PLCER-Positive HER2-Negative Breast Cancer
Active, not recruitingInterventional · Not applicableNCT05155605 ↗The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening PopulationCora SternbergPIInterventionDevice: Multi-Cancer Early Detection TestDatesDec 2021 – Feb 2026SponsorGrail, LLCEarly Detection of CancerCancer
RecruitingInterventional · Phase 1/2NCT05361174 ↗A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerBarbara MaPIInterventionBiological: IOV-4001DatesJul 2022 – Sep 2027 (est.)SponsorIovance Biotherapeutics, IncUnresectable MelanomaMetastatic MelanomaStage III Non-small Cell Lung Cancer+1 more
Active, not recruitingInterventional · Phase 2NCT05482971 ↗A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential ThrombocythemiaGhaith Abu-ZeinahPIInterventionDrug: Ropeginterferon alfa-2b-njft (P1101)DatesSep 2022 – May 2025SponsorPharmaEssentiaEssential Thrombocythemia
Active, not recruitingInterventional · Phase 1/2NCT05520567 ↗A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction ChemotherapyGail J RobozPIInterventionDrug: Gilteritinib · Drug: Venetoclax · Drug: AzacitidineDatesJan 2023 – Jul 2028 (est.)SponsorAstellas Pharma Inc.Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
RecruitingInterventional · Phase 1/2NCT05970497 ↗A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor MalignanciesAnna C PavlickPIInterventionBiological: KB707 · Drug: Opdualag · Drug: KEYTRUDA ®( Pembrolizumab)DatesOct 2023 – Jul 2027 (est.)SponsorKrystal Biotech, Inc.CancerMelanoma Stage IIIMelanoma Stage IV+1 more
RecruitingInterventional · Phase 2NCT06623656 ↗Multicenter Randomized Phase II Trial of Neoadjuvant Radioimmunotherapy Versus Chemoimmunotherapy in Patients With Clinical Stages IB-III (N2) Non-small Cell Lung CancerNasser K AltorkiPIInterventionDrug: Cemiplimab · Drug: Platinum based chemotherapy · Radiation: Stereotactic body radiation therapyDatesFeb 2025 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityCarcinoma, Non-Small-Cell Lung
RecruitingInterventional · Phase 1/2NCT06634589 ↗A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell MalignanciesJohn AllanPIInterventionDrug: Tacabrutideg · Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Mosunetuzumab · Drug: Glofitamab · Drug: ObinutuzumabDatesNov 2024 – Dec 2028 (est.)SponsorBeiGene USAB-cell MalignancyRelapsed CancerRefractory Cancer+1 more
RecruitingInterventional · Phase 1/2NCT06892522 ↗A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MMMateo Mejia SaldarriagaPIInterventionDrug: Etentamig · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab · Drug: Carfilzomib · Drug: Mezigdomide · Drug: Iberdomide · Drug: ABBV-2001 · Drug: PomalidomideDatesJun 2025 – Dec 2035 (est.)SponsorAbbVie Inc.Multiple Myeloma
Enrolling by invitationInterventional · Not applicableNCT07046832 ↗Clinical Evaluation of an Intra-procedural 3D Needle Guidance Platform for Soft Tissue Tumors or Organs Requiring Percutaneous Biopsy as an Adjunct to Standard Image GuidanceBradley B PuaPIInterventionDevice: Augmented Reality Guided Biopsy · Device: Ultrasound Guided BiopsyDatesJun 2025 – Jun 2027 (est.)SponsorMediView XROncologyInterventional RadiologyLiver Carcinoma+2 more
RecruitingInterventional · Phase 2NCT07216443 ↗A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeAlexandra Gomez ArteagaPIInterventionBiological: Orca-TDatesDec 2025 – Nov 2027 (est.)SponsorOrca BiosystemsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
CompletedInterventional · Phase 1/2NCT02158858 ↗A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)Joseph M ScanduraPIInterventionDrug: Pelabresib · Drug: RuxolitinibDatesJul 2014 – Jan 2025· Results postedSponsorConstellation PharmaceuticalsMyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative Neoplasm+11 more